首   页
所况介绍
科研团队
科研成果
美国药学学会-福州大学分会
人才招聘
通知系统
2012年-2013年发表的论文
发布日期:2012-08-25    浏览次数:

1. Meng, J., Yang, X.D., Jia. L., Liang, X.J., Wang, C. Impact of nanoparticles on cardiovascular diseases: modulating metabolism and function of endothelial cells. Curr. Drug Metab. 13: 1123-29; 2012. IF5.113
 
2.Jia, X., Jia, L*.Nanomaterials improve biological functions of photosensitizers used for photodynamic therapy.Curr. Drug Metab. 13: 1119-22, 2012. IF5.113
 
3.Xue, X., You, S., Zhang, Q., Wu, Y., Zou, GZ., Wang, PC., Zhao, YL., Xu, Y., Jia, L.,  Zhang, X., Liang, XJ. Mitaplatin increases sensitivity of tumor cells to cisplatin by inducingmitochondrial dysfunction.Mol. Pharmaceutics 9:634−644 ;2012.IF4.782
 
4.Shao, J., Xue, JP., Dai, YC., Liu, H, Jia*, L, Chen, NS., Huang, JL. Inhibition of human hepatocellular carcinoma HepG2 by phthalocyanine photosensitizer Photocyin: ROS production, apoptosis, and cell cycle arrest. Eur. J. Cancer. 48: 2086-96; 2012. ISSN:0959-8049; IF5.536
 
5.Meng, J., Xing, J., Wang, Y., Lu, Y., Zhao, YL., Gao, X., Wang, P.C., Jia, L. Liang, XJ. Epigenetic modulation of human breast cancer by metallofullerene nanoparticles: in vitro analysis and in vivo treatment.Nanoscale. 3: 4713-19; 2011.IF5.914
 
6.Zhang, F., Xie, JP., Shao, JW., Jia*, L. Compilation of 222 Drugs’ Plasma Protein BindingData and Guidance for Study Designs. Drug Discovery Today 17:475-495,2012. IF6.828
 
7.Jia, L.*Lu, Y., Shao, J., Liang, XJ., Xu Y. Nanoproteomics: a new spin from emerging links between nanotechnology and proteomics. Trends Biotech.31:99-107, 2013.IF9.11
 
8.Xu, Y.,Jia, L. Nanoscaled Proteomic Analysis. 64-81, Chapter 4th In Nanopharmaceuticals Ed by Liang. World Scientific Publishing, Singapore. 2012.
 
9.Jia*,L., Shao,JW.,Yu, S.Cancer metastasis calls for a strategic change of the global anti-cancer drug development in the 21st century. Acta Pharm. Sinica. 2012.
 
10.Shao, JW., Dai,Y.,Zou,WT., Xue, JP.,Ye, J., Jia*, L. Intracellular distribution and mechanisms of actions of photosensitizer Zinc (II)-phthalocyanine against human hepatocellular carcinoma HepG2 cells. Cancer Lett. 330:49-56,2013. IF4.2
 
11.Xie, JJ.,Shao, JW.,Lu,Y.,Chen, JZ., Wang,J.,Yu SH.,Jia, L*. Separation of ginseng active ingredients and their roles in cancer metastasis supplementary therapy. Curr. Drug Metabo. 14:614-621;2013.
 
12.Jiang, Z.,Shao, J., Chen, M,Hu, Y.,Wang, J.,Jia*, L. A novel SPE-HPLC method for simultaneous determination of selected sulfonated phthalocyanine zinc complexes in mouse plasma following cassette dosing. Analyst DOI:10.1039/C3AN00744H; 2013. IF4.2
 
13.Jia*, L. Science Requires Coexisting of Opposite Opinions:“One Country, Two Systems” Pharmaceutical Reg. Affairs: Open AccessISSN:2167-7689; 1(4):1000e114;2012
 
14.Shao, J., Jia*, L. Potential serious interactions between nutraceutical ginseng and warfarin in patients with ischemic stroke. Trends Pharmacol. Sci. 34(2):85-86, 2013. IF10.927
 
15.Yin, J.J., Sharma, S., Shumyak, S.P., Wang, Z.X., Zhou, Z., Zhang, Y., Guo, P., Li, C.Z., Kanwar, J.R., Yang, T.X., Mohapatra, S.S., Liu, W., Duan, W., Wang, J., Li, Q., Zhang, X., Tan, J., Jia, L. Liang, J., Wei, M.Q., Li, X., Zhou, S.F. Synthesis and Biological Evaluation of a Novel Cancer Treatment Based on Folic Acid Receptor-Targeted, β-Cyclodextrin-Based Drug Complexes for Cancer Treatment. PLoS ONE 8(5): e62289; 2013.
 
16.Jiang, Z., Shao, J., Wang, J., Jia*, L. Pharmaceutical development, composition and quantitative analysis of phthalocyanine as the photosensitizer for cancer photodynamic therapy. J. Pharm. Biomed. Anal. 10.1016/j.jpba.2013.05.014, 2013.
 
 



 



上一篇: 2014年发表的论文